japetus
Moderator
Seriously though..look at those "art" projects in Denver Airport...CREEPY shit.
V2a
Active member
LOL, that's what started this thread!
V2a
Active member
Well said!
japetus
Moderator
I actually think it's impressive that you remember that post! You have a good memory! Alright, gloves off as far as personal life shit in Off Topic now. I get it. Let's have some fun boys! HC 2002 time. Gird your loins! Wait a min, what am I saying? Half of you guys are canucks! Ole Justin will fuck you more than I ever could.
Last edited:
V2a
Active member
Perhaps.
But I try not to shit on any amp designer/builder. Ideas have to come from somewhere, lol.
V2a
Active member
Findthetone1
Well-known member
Ahhhh. I just love to see young love bloom in the springtime....
Wizard of Ozz
Well-known member
Metalhex
Well-known member
So with the Texas school shooting today we learned that the kid shot his grandma before leaving to shoot up a school....just like Adam Lanza/Sandy Hook.
He crashed his vehicle before going into the school....same as Lanza. Odd to say the least.
He crashed his vehicle before going into the school....same as Lanza. Odd to say the least.
Findthetone1
Well-known member
It's almost as if someone had given them instructions..........
jaxadam
Well-known member
Man that is a beautiful avatar bro, is that your MyFitnessPal or bodybuilding.com forums avatar too?
V2a
Active member
Let's stick to discussing airports and tinfoil supply issues in this thread! Add in covid, vaxxxes, and stupid politicians if you must, but no mass murder!
jaxadam
Well-known member
Nope, it's a rig-talk exclusive
That shit is beautiful bro, but you need to get a better razor and a tan!
jaxadam
Well-known member
Aw shucks, I have a full body blush on now, so no need for the tan
:fistbump:
Findthetone1
Well-known member
LOL.
Any of you guys remember the kid in school that would copy someone else's book report VERBATUM and get caught by the teacher and then ague with the teacher for a week that they didn't copy it?
That's Captain Mirror Selfie folks...
Any of you guys remember the kid in school that would copy someone else's book report VERBATUM and get caught by the teacher and then ague with the teacher for a week that they didn't copy it?
That's Captain Mirror Selfie folks...
SQUAREHEAD
Well-known member
Mass murder? You mean like Zelensky and his Nazi regime burning / skinning / killing tens of thousands over the last decade, his own citizens you mean?
You mean the same Ukraine that the Washington Post and the New York Times have spent the last decade along with all other media sources writing hundreds of articles of how evil and corrupt the Ukraine Govt and military are?
That mass genocide?
H
harddriver
Well-known member
https://www.israelnationalnews.com/news/328102
Direct link to BMJ/Yale study follows: Study published 4/18/22
https://www.medrxiv.org/content/10.1101/2022.04.18.22271936v1.full
Vaccines against the coronavirus may impair the body’s ability to produce a key type of antibody, thus potentially limiting the immune system’s defenses against mutated strains of the virus, a new study suggests.
The study draws upon data collected during Moderna’s randomized control trial for its mRNA SARS-CoV-2 vaccine, from July 2020 through March 2021.
Researchers looked at participants who tested positive for the coronavirus during the trial, comparing serum levels of specific types of antibodies, based on vaccination status, as well as viral load.
In particular, the study looks at the antibody response to the virus’ nucleocapsid protein core, using the anti-nucleocapsid antibodies levels (anti-N Abs) as a marker for comprehensive immune system response to the virus, as opposed to the narrower response to the spike protein. Variants of SARS-CoV-2 with mutated spike proteins have been a subject of concern for the reliance of vaccinated immunity on antibodies targeting the s-proteins of the original variant.
As expected, serum levels of the anti-nucleocapsid antibodies varied based on measured viral load in both the placebo and vaccine cohorts, with participants who had higher viral loads found to have higher levels of neutralizing anti-nucleocapsid antibodies.
Researchers also found a pronounced difference, however, in the levels of anti-nucleocapsid antibodies between vaccinated participants and members of the placebo cohort, even when the study controlled for viral load.
Trial participants who were given the placebo, rather than the vaccine, and became infected during the trial were found to have significantly higher levels of the neutralizing anti-nucleocapsid antibodies than vaccinated participants who had comparable viral loads.
Approximately 60% of participants from the placebo cohort who experienced very mild infection, with low viral loads, were found to have anti-nucleocapsid antibodies, compared to roughly 10% of vaccinated subjects.
Among those with higher viral loads – qualifying as mild cases, rather than very mild – 71% of the unvaccinated developed anti-nucleocapsid antibodies, compared to just 15% of those in the vaccine group.
Of all unvaccinated subjects who had been diagnosed with the virus during the trial, nearly all (93%) had measurable levels of anti-nucleocapsid antibodies, compared to less than half (40%) of those in the vaccine cohort.
“While an increase in seroreversion cannot be ruled out, given the short time frame the more likely explanation is a vaccine-induced reduction in seroconversion,” researchers wrote, suggesting that trial participants given the vaccine had reduced levels of the anti-nucleocapsid antibodies as a direct result of the vaccine’s narrow focus on the spike protein.
The researchers also hinted that the diminished anti-nucleocapsid antibody response among the vaccinated could lead to undercounting of breakthrough cases, when measured by antibody sampling.
“Even with frequent serosampling, serosurveys that rely on antibodies to the N protein may underestimate within-community transmission dynamics.”
Direct link to BMJ/Yale study follows: Study published 4/18/22
https://www.medrxiv.org/content/10.1101/2022.04.18.22271936v1.full
Vaccines against the coronavirus may impair the body’s ability to produce a key type of antibody, thus potentially limiting the immune system’s defenses against mutated strains of the virus, a new study suggests.
The study draws upon data collected during Moderna’s randomized control trial for its mRNA SARS-CoV-2 vaccine, from July 2020 through March 2021.
Researchers looked at participants who tested positive for the coronavirus during the trial, comparing serum levels of specific types of antibodies, based on vaccination status, as well as viral load.
In particular, the study looks at the antibody response to the virus’ nucleocapsid protein core, using the anti-nucleocapsid antibodies levels (anti-N Abs) as a marker for comprehensive immune system response to the virus, as opposed to the narrower response to the spike protein. Variants of SARS-CoV-2 with mutated spike proteins have been a subject of concern for the reliance of vaccinated immunity on antibodies targeting the s-proteins of the original variant.
As expected, serum levels of the anti-nucleocapsid antibodies varied based on measured viral load in both the placebo and vaccine cohorts, with participants who had higher viral loads found to have higher levels of neutralizing anti-nucleocapsid antibodies.
Researchers also found a pronounced difference, however, in the levels of anti-nucleocapsid antibodies between vaccinated participants and members of the placebo cohort, even when the study controlled for viral load.
Trial participants who were given the placebo, rather than the vaccine, and became infected during the trial were found to have significantly higher levels of the neutralizing anti-nucleocapsid antibodies than vaccinated participants who had comparable viral loads.
Approximately 60% of participants from the placebo cohort who experienced very mild infection, with low viral loads, were found to have anti-nucleocapsid antibodies, compared to roughly 10% of vaccinated subjects.
Among those with higher viral loads – qualifying as mild cases, rather than very mild – 71% of the unvaccinated developed anti-nucleocapsid antibodies, compared to just 15% of those in the vaccine group.
Of all unvaccinated subjects who had been diagnosed with the virus during the trial, nearly all (93%) had measurable levels of anti-nucleocapsid antibodies, compared to less than half (40%) of those in the vaccine cohort.
“While an increase in seroreversion cannot be ruled out, given the short time frame the more likely explanation is a vaccine-induced reduction in seroconversion,” researchers wrote, suggesting that trial participants given the vaccine had reduced levels of the anti-nucleocapsid antibodies as a direct result of the vaccine’s narrow focus on the spike protein.
The researchers also hinted that the diminished anti-nucleocapsid antibody response among the vaccinated could lead to undercounting of breakthrough cases, when measured by antibody sampling.
“Even with frequent serosampling, serosurveys that rely on antibodies to the N protein may underestimate within-community transmission dynamics.”